Healthcare · Medical Instruments Supplies · NASDAQ
LeMaitre Vascular (LMAT) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $1.85B, a trailing price-to-earnings ratio of 29.4 and a free-cash-flow yield of 4.0%. Over the most recent reported fiscal year, revenue grew 13.5% and free cash flow per share grew 99.1%. Nama's AI scorecard rates it Buy, 7.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Buy · 7.2/10
Clearly positive, short of the top band. As of Nov 7, 2026.
Momentum
Lagging · -7.3% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-31.4%
How far the last close sits under the highest price of the past five years.
Market cap
$1.85B
Trailing P/E
29.4
Price / book
4.4
Price / sales
7.0
FCF yield
4.0%
Dividend yield
1.2%
Gross margin
72.9%
Operating margin
29.5%
Net margin
25.0%
Revenue growth (YoY)
+13.5%
Revenue growth (3-yr annual)
+15.6%
EPS growth (YoY)
+29.4%
FCF/share growth (YoY)
+99.1%
Beta
0.5
Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Instruments Supplies
LMAT earnings
Next report: Feb 24, 2027 (Q4 2026, EPS estimate $0.78).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
$0.65
$0.69
-5.8%
$67.97M
Q2 2026
Aug 4, 2026
$0.74
$0.81
-8.6%
$70.38M
Q1 2026
May 5, 2026
$0.68
$0.66
+3.0%
$66.55M
Q4 2025
Feb 25, 2026
$0.68
$0.66
+3.0%
$64.45M
LMAT analyst price target
Median target $100.00 from 7 analysts, ranging $81.00 – $132.00.
Nama's AI scorecard currently rates LeMaitre Vascular Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LMAT's P/E ratio?
LeMaitre Vascular trades at a trailing price-to-earnings ratio of 29.4.
When does LMAT report earnings?
LeMaitre Vascular's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $0.78.
What is the LMAT price target?
The median analyst price target from 7 analysts is $100.00, with a range of $81.00 – $132.00.
Is LMAT Shariah compliant?
Nama's AAOIFI-style screen reads LeMaitre Vascular as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.